Arcturus Therapeutics

From WikiMD's Wellness Encyclopedia

Arcturus Therapeutics is a biotechnology company that specializes in the development of RNA medicines. The company's primary focus is on rare diseases, viral infections, and liver diseases. Arcturus Therapeutics utilizes a proprietary lipid nanoparticle delivery system known as LUNAR® to deliver its RNA medicines to cells.

History[edit | edit source]

Arcturus Therapeutics was founded in 2013 by Joseph Payne and Pad Chivukula. The company was initially based in San Diego, California. In 2020, Arcturus Therapeutics began clinical trials for a COVID-19 vaccine, known as ARCT-021.

Technology[edit | edit source]

Arcturus Therapeutics uses a proprietary lipid nanoparticle delivery system, LUNAR®, to deliver RNA medicines to cells. This technology allows for the targeted delivery of RNA medicines to specific cells in the body. The company also utilizes a proprietary RNA engineering platform, STARR™, to create RNA medicines that can be used to treat a variety of diseases.

Products[edit | edit source]

Arcturus Therapeutics has several products in its pipeline, including treatments for rare diseases, viral infections, and liver diseases. The company's most advanced product is ARCT-021, a vaccine for COVID-19 that is currently in clinical trials.

Clinical Trials[edit | edit source]

Arcturus Therapeutics has conducted several clinical trials to test the safety and efficacy of its products. The most notable of these is the ongoing trial for ARCT-021, the company's COVID-19 vaccine.

See Also[edit | edit source]

References[edit | edit source]


Contributors: Prab R. Tumpati, MD